Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects

This study has been completed.
Sponsor:
Collaborators:
Juvenile Diabetes Research Foundation
Amylin Pharmaceuticals, LLC.
Merck Sharp & Dohme Corp.
Pfizer
Eli Lilly and Company
Takeda
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Novartis
Information provided by (Responsible Party):
Foundation for the National Institutes of Health
ClinicalTrials.gov Identifier:
NCT01454973
First received: October 17, 2011
Last updated: August 9, 2012
Last verified: August 2012
  Purpose

A multi-year clinical study to improve tools for measuring the function of insulin-producing beta cells in people with type 2 diabetes mellitus.


Condition
Type 2 Diabetes

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects

Resource links provided by NLM:


Further study details as provided by Foundation for the National Institutes of Health:

Enrollment: 25
Study Start Date: October 2011
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Healthy obese individuals

Detailed Description:

A three-year observational study to standardize the meal tolerance and maximum stimulational tests for measuring beta cell function in the clinical setting. It also aims to improve methods for the early prediction of the long-term response to an intervention and for identification of patients at risk for rapid beta cell function deterioration, thereby enabling future clinical studies that examine diabetes progression.

  Eligibility

Ages Eligible for Study:   30 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Healthy obese individuals

Criteria

Inclusion Criteria:

  1. Ability to give informed consent and comply with all study requirements
  2. Overweight and obese, generally healthy men and women. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests.
  3. Women of child-bearing potential are allowed (but must agree to use non-hormonal contraception and not plan to become pregnant for the duration of the study. Must agree to maintain the same contraceptive measures throughout the study. Acceptable contraceptive methods for female subjects of childbearing potential include one of the following:

    • Abstinence.
    • One (1) of the following methods:

      • Tubal ligation
      • Copper-containing intrauterine device (IUD)
      • Condom AND spermicidal foam/gel/film/cream/suppository
      • Male partner who has had a vasectomy for at least 6 months.
  4. It is required that all male subjects use an acceptable method of contraception (as outlined below), starting from the first dose of study medication and continuing for at least 28 days after the last dose of study drug:

    • Abstinence
    • A condom AND one of the following:
    • Vasectomy for more than 6 months. Female partner who meets one of the following conditions: has had a tubal ligation, hysterectomy, or bilateral oophorectomy; or is post menopausal
  5. BMI 27-40; stable weight (less than 3% change in past 3 months) Age Range: 30-65
  6. No history of diabetes mellitus or impaired glucose tolerance (and impaired fasting glucose)
  7. Other conditions may be allowed, if medically stable and controlled within acceptable limits, including: hypertension, dyslipidemia, osteoarthritis, osteoporosis
  8. Smokers allowed, but must be able to participate on inpatient stay and not smoke
  9. Normal oral glucose tolerance test response (see exclusion criteria)

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic or clinical findings at Screening.
  2. Any condition possibly affecting absorption (eg, gastrectomy, malabsorption syndromes, abdominal surgery other than appendectomy, cholecystectomy or hysterectomy).
  3. Use of unacceptable medications (see Appendix A)
  4. A positive urine drug screen.
  5. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
  6. Treatment with an investigational drug within 30 days or 5 half-lives preceding the first dose of study medication.
  7. 12 lead ECG demonstrating QTc >450 msec at Screening for males, 470 msec for females. If QTc exceeds 450/470 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
  8. Supine blood pressure >=140 mm Hg (systolic) or 90 mm Hg (diastolic), on a single measurement. If elevated, confirm by a single repeat, following at least 10 minutes of rest.
  9. Screening fasting serum glucose >=100 mg/dL or HbA1c >6.5%, confirmed by a single repeat if deemed necessary.
  10. Abnormal oral glucose tolerance test (see below for definition of abnormal).
  11. Screening serum alanine transaminase (ALT) or serum aspartate transaminase (AST) greater than 2X the upper limit of the laboratory reference range.
  12. Elevated fasting triglycerides at screening (>500 mg/dL), confirmed by a single repeat if deemed necessary.
  13. Pregnant or nursing females; inability to use effective contraception.
  14. Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
  15. Participation in a clinical biomedical research study within prior two months may be excluded, depending on study type and details.
  16. History of sensitivity to heparin or heparin-induced thrombocytopenia, if utilized by the site for blood draws.
  17. Unwilling or unable to comply with directions and procedures described in this protocol.
  18. Subject is the Investigator or a sub-Investigator, research assistant, pharmacist, study coordinator, other staff, or a relative of study personnel directly involved with the conduct of the study.
  19. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01454973

Locations
United States, Texas
ICON Development Solutions, Gault Lane
San Antonio, Texas, United States, 78209
Sponsors and Collaborators
Foundation for the National Institutes of Health
Juvenile Diabetes Research Foundation
Amylin Pharmaceuticals, LLC.
Merck Sharp & Dohme Corp.
Pfizer
Eli Lilly and Company
Takeda
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Novartis
Investigators
Principal Investigator: George Atiee, M.D. ICON Development Solutions
  More Information

No publications provided

Responsible Party: Foundation for the National Institutes of Health
ClinicalTrials.gov Identifier: NCT01454973     History of Changes
Other Study ID Numbers: Beta Cell - Protocol 1a
Study First Received: October 17, 2011
Last Updated: August 9, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Foundation for the National Institutes of Health:
type 2 diabetes
beta cell function
meal tolerance test
maximum stimulation test
method standardization
insulin secretion

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 28, 2014